- Home
- FMAO vs SKYE Comparison
FMAO vs SKYE Comparison
Compare FMAO & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMAO
- SKYE
- Stock Information
- Founded
- FMAO 1897
- SKYE 2012
- Country
- FMAO United States
- SKYE United States
- Employees
- FMAO N/A
- SKYE N/A
- Industry
- FMAO Savings Institutions
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- FMAO Finance
- SKYE Health Care
- Exchange
- FMAO Nasdaq
- SKYE Nasdaq
- Market Cap
- FMAO 359.3M
- SKYE 108.5M
- IPO Year
- FMAO N/A
- SKYE N/A
- Fundamental
- Price
- FMAO $26.52
- SKYE $3.94
- Analyst Decision
- FMAO
- SKYE Buy
- Analyst Count
- FMAO 0
- SKYE 7
- Target Price
- FMAO N/A
- SKYE $15.50
- AVG Volume (30 Days)
- FMAO 16.9K
- SKYE 319.5K
- Earning Date
- FMAO 10-29-2025
- SKYE 11-06-2025
- Dividend Yield
- FMAO 3.36%
- SKYE N/A
- EPS Growth
- FMAO 38.39
- SKYE N/A
- EPS
- FMAO 2.16
- SKYE N/A
- Revenue
- FMAO $108,632,000.00
- SKYE N/A
- Revenue This Year
- FMAO $3.38
- SKYE N/A
- Revenue Next Year
- FMAO $6.39
- SKYE N/A
- P/E Ratio
- FMAO $12.20
- SKYE N/A
- Revenue Growth
- FMAO 13.86
- SKYE N/A
- 52 Week Low
- FMAO $20.88
- SKYE $1.14
- 52 Week High
- FMAO $34.15
- SKYE $5.96
- Technical
- Relative Strength Index (RSI)
- FMAO 55.54
- SKYE 54.83
- Support Level
- FMAO $25.08
- SKYE $3.71
- Resistance Level
- FMAO $26.50
- SKYE $4.55
- Average True Range (ATR)
- FMAO 0.81
- SKYE 0.32
- MACD
- FMAO -0.04
- SKYE 0.01
- Stochastic Oscillator
- FMAO 69.01
- SKYE 51.97
About FMAO Farmers & Merchants Bancorp Inc.
Farmers & Merchants Bancorp Inc is a holding company based in Ohio. The company is engaged in general commercial banking business. The activities of the company include commercial, agricultural and residential mortgages as well as consumer and credit card lending activities.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.